Get the Stockscreener App
2.18
4.81%
0.10
After Hours:
2.16
-0.02
-0.92%
iBio Inc stock is traded at $2.18, with a volume of 675.19K.
It is up +4.81% in the last 24 hours and down -24.04% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$2.08
Open:
$2.15
24h Volume:
675.19K
Relative Volume:
0.40
Market Cap:
$75.30M
Revenue:
$300.00K
Net Income/Loss:
$-24.74M
P/E Ratio:
-2.167
EPS:
-1.006
Net Cash Flow:
$-19.19M
1W Performance:
-0.46%
1M Performance:
-24.04%
6M Performance:
+173.63%
1Y Performance:
-50.57%
1-Day Range:
$2.12
$2.24
1-Week Range:
$1.9801
$2.30
52-Week Range:
$0.5562
$4.74
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.18 | 71.85M | 300.00K | -24.74M | -19.19M | -1.006 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
Panic Selling: Is iBio Inc impacted by rising ratesWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Insider Buying: Felipe Duran Acquires Shares of iBio Inc (IBIO) - GuruFocus
INB.bio Launches Rebuilt Ai-Powered Affiliate Crm Platform - marketscreener.com
Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock - MarketBeat
iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares - MarketBeat
iBio CFO Duran acquired $50k in shares on March 19 - Investing.com
iBio director Brenner buys $24918 in company stock By Investing.com - Investing.com Australia
iBio director Brenner buys $24918 in company stock - Investing.com
IBIO | iBio, Inc. Common Stock Insider Trading - Quiver Quantitative
iBio CFO Duran acquired $50k in shares on March 19 By Investing.com - Investing.com South Africa
CFO adds 24,835 iBio (NYSE: IBIO) shares in open-market purchase - Stock Titan
iBio (IBIO) director makes open-market purchase of 12,336 shares - Stock Titan
Aug Action: Is iBio Inc a speculative investmentTrade Analysis Report & Weekly High Return Forecasts - baoquankhu1.vn
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Ibio (IBIO) Receives a Buy from LifeSci Capital - The Globe and Mail
History Review: Can iBio Inc stock double in the next yearTake Profit & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
iBio (NASDAQ:IBIO) Cut to Sell at Wall Street Zen - MarketBeat
Aug Movers: Is iBio Inc impacted by rising rates2026 Earnings Surprises & Weekly Top Stock Performers List - baoquankhu1.vn
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 - MarketBeat
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
IBIO: Analyst Keay Nakae Reaffirms 'Buy' Rating with $5.00 Price Target | IBIO Stock News - GuruFocus
Aug Opening: How do insiders feel about iBio IncQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion By Investing.com - Investing.com South Africa
Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion - Investing.com India
VIX Spike: Is IBIO in a long term uptrend2026 PreEarnings & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
iBio (NASDAQ:IBIO) Given Buy Rating at Chardan Capital - MarketBeat
iBio (IBIO) to Discuss Pipeline Expansion in Upcoming Conference Call - GuruFocus
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - The Manila Times
Stop Loss: How sensitive is iBio Inc to inflationWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
iBio reports fat reduction in primate obesity study By Investing.com - Investing.com Nigeria
Ibio SEC Filings - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Highs Report: Is iBio Inc a turnaround storyRate Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
IBIO: Advancing novel antibody therapies for obesity and cardiometabolic disease with strong clinical momentum - TradingView
Jones Trading reiterates iBio stock rating on obesity drug data - Investing.com
Jones Trading reiterates iBio stock rating on obesity drug data By Investing.com - Investing.com UK
iBio Reports Promising Preclinical Results for IBIO-610 Activin E Antibody in Fat-Selective Weight Loss for Obesity and Cardiometabolic Diseases 1 - Minichart
IBIO: Innovative antibody pipeline aims for fat-specific weight loss and muscle preservation in obesity - TradingView
iBio reports fat reduction in primate obesity study - Investing.com
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential - TipRanks
iBio (IBIO) Reports Promising Preclinical Results for Obesity Tr - GuruFocus
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss - Bitget
Primate obesity study backs iBio fat-loss antibody, twice-yearly dosing potential - Stock Titan
[EFFECT] iBio, Inc. SEC Filing - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Cash per share of iBio, Inc. – MUN:0JV0 - TradingView
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ:IBIO) Upgraded by JonesTrading to Strong-Buy Rating - MarketBeat
Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation - Nasdaq
JonesTrading Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
iBio (IBIO) Receives New 'Buy' Rating from Jones Trading | IBIO Stock News - GuruFocus
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):